What happened
Georgetown's Lombardi Comprehensive Cancer Center modelled the lifetime balance between curing breast cancer and the biological ageing caused by cytotoxic chemotherapy, published in JAMA Network Open on 10 November 2026 (DOI 10.1001/jamanetworkopen.2026.43008). The model, covering women aged 30 to 79, estimated that the most cytotoxic regimens were associated with 9.4 fewer years of remaining life, because ageing-related diseases appeared earlier.
It is the first study to estimate this lifetime trade-off in numbers — the benefit of curing the cancer against the cost of faster biological ageing.
Why it matters
Survivorship is now the long tail of cancer care: millions of women live decades after breast cancer, and the question is no longer only whether the treatment works, but what it costs over a lifetime. A number like 9.4 years gives follow-up care a target — monitoring heart, bone and cognition in survivors — even if the number itself comes from a model.
What comes next
The effects take years to appear, and a model needs checking against real long-term follow-up. The angle to watch is survivorship care: whether clinics start screening former chemotherapy patients for ageing-related disease earlier than they do now.
Simulation modelling of a population (women aged 30 to 79), not a trial that followed real patients for decades. The effects take years to appear. This is not a reason to refuse chemotherapy: it cures cancer. The story is about follow-up care for survivors.